The phase III LAGOON trial missed its primary endpoint of Overall Survival (OS), showing lurbinectedin monotherapy underperformed investigator's choice chemotherapy in second-line small cell lung cancer (SCLC). Jazz Pharmaceuticals said on August 3, 2026 that, in alignment with the FDA, it will submit a labeling supplement in Q3 2026 to remove the second-line metastatic SCLC indication granted under accelerated approval in 2020; the withdrawal has not yet taken effect, and the first-line maintenance indication with atezolizumab is not affected (Jazz Q2 2026 results, 3-Aug-2026). Other research shared includes real-world evidence supporting the safety of immunotherapy in advanced NSCLC patients with pre-existing pericardial effusions.
“🚨 Jazz + FDA are withdrawing lurbinectedin's accelerated approval in 2L metastatic SCLC after LAGOON missed OS.”
— @LauraAlderMD · Lurbinectedin Approval Withdrawal · View post ↗
“Lurbinectedin monotherapy underperformed investigator's choice chemo on OS.”
— @mgonzalezvelMD · LAGOON Trial Results · View post ↗
“Our findings provide reassuring real-world evidence that may help guide treatment decisions.”
— @NarjustFlorezMD · Immunotherapy Safety in NSCLC · View post ↗
“AYA Lung Cancer - has different risk factor and genomic profile as compared to the usual NSCLC.”
— @Jani_Chinmay · AYA Lung Cancer · View post ↗Updated breast cancer treatment algorithms for both early-stage and metastatic disease (MBC) by subtype are being shared within the breast oncology community. The resource from Dr. Ilana Schlam provides a current overview of treatment pathways.
“It’s that time of year again for Dr @IlanaSchlam’s excellent update of breast cancer treatment algorithms, early stage and MBC, by subtype.”
— @stage4kelly · Treatment Algorithms · View post ↗📌 Amplified by @KolPulseAI
A subgroup analysis of the DESTINY-PanTumor02 trial evaluated the efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors. Separately, a new pipeline has been published for systematically identifying cell-surface targets in hepatocellular carcinoma (HCC) for theranostics development.
“We asked a simple question: can we systematically find cell-surface targets in #HCC for #theranostics development?”
— @freddyeescorcia · HCC Theranostics · View post ↗
“Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02 - ESMO Open”
— @Erman_Akkus · DESTINY-PanTumor02 · View post ↗📌 Amplified by @KolPulseAI
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The US FDA approved Pluvicto (lutetium-177 vipivotide tetraxetan) for patients with PSMA-positive metastatic androgen pathway modulation-sensitive prostate cancer (mAPMS/mHSPC), based on the Phase 3 PSMAddition trial, which met its primary endpoint with an rPFS hazard ratio of 0.72 (95% CI 0.58-0.90; p=0.002; ESMO 2025 LBA6, DCO1 13-Jan-2025) while overall survival data remain immature. Other discussions include findings from the VESPER trial, where the basal molecular subtype was an independent prognostic factor for OS in MIBC treated with neoadjuvant chemotherapy, and new International Bladder Cancer Group recommendations on integrating validated biomarkers into care.
“Just in👉today @US_FDA approved Pluvicto (Lutetium-177)for PSMA+ metastatic androgen pathway modulation-sensitive #prostatecancer (mAPMS/mHSPC), based on the results of ph3 PSMAddition trial👇”
— @neerajaiims · Pluvicto FDA Approval · View post ↗📌 Amplified by @KolPulseAI
“⚡️ VESPER trial: basal molecular subtype is an independent prognostic factor for OS in MIBC treated with neoadjuvant chemotherapy, regardless of the regimen used.”
— @drenriquegrande · VESPER Trial Data · View post ↗
“biomarkers don't improve care simply because they're "novel or new" They improve care when they're validated, reproducible, and actually change clinical decisions 🧵”
— @UroDocAsh · Bladder Cancer Biomarkers · View post ↗
“Can intermittent maximal androgen blockade reduce treatment burden while maintaining outcomes in selected men with #mHSPC receiving ADT + ARPI? That's the question we're addressing.”
— @BertrandTOMBAL · DE-ESCALATE Trial Design · View post ↗The 2-year follow-up of the MajesTEC-1 China cohort for teclistamab in heavily pretreated relapsed/refractory multiple myeloma showed a 76.9% ORR and a median PFS of 25.1 months, with high rates of Grade 3/4 infections (76.9%). New International Myeloma Working Group recommendations for solitary plasmacytoma establish definitive radiation therapy as the standard of care. Ongoing debate centers on risk stratification for smoldering myeloma, with discussion on the relative importance of clone size versus genomics.
“Definitive RT is SOC, including patients with minimal (<10%) bone marrow involvement”
— @kahvecioglu_a · Solitary Plasmacytoma Guidelines · View post ↗
“🔹 ORR: 76.9% 🔹 100% of responders achieved ≥VGPR 🔹 75% achieved ≥CR 🔹 Median PFS: 25.1 months 🔹 Median OS: Not reached”
— @Abdallah81MD · Teclistamab Efficacy (MajesTEC-1) · View post ↗“📌 Grade 3/4 infections: 76.9% 📌 Nearly all patients developed infections 📌 Hypogammaglobulinemia occurred in >90%”
— @Abdallah81MD · Teclistamab Toxicity (MajesTEC-1) · View post ↗
“A major fallacy in smoldering myeloma is to think we can predict outcome with better and deeper genomics. No. Genomics alone is not great at predicting outcome on its own. At least not what we have so far. Clone size (Tumor burden) is critical and actually does better.”
— @VincentRK · Smoldering Myeloma Risk Stratification · View post ↗The QuANTUM-First trial demonstrated an overall survival benefit with quizartinib plus 7+3 chemotherapy for FLT3-ITD acute myeloid leukemia (AML). Other AML data includes the OPTI-AML trial, where a 14-day course of venetoclax was not non-inferior to a 28-day course, and the KOMET-007 trial of ziftomenib plus 7+3, which showed a 90-96% composite complete remission rate. In myelofibrosis, the SENTRY trial showed that adding selinexor to ruxolitinib increased SVR35.
“QuANTUM-First: Quizartinib + 7+3 for FLT3-ITD AML >> OS (primary endpoint) #leusm”
— @smbenlazar · QuANTUM-First Trial · View post ↗
“1️⃣OPTI-AML:14-day Ven not non-inferior to 28-day (esp. NPM1/IDH)”
— @OncUpdates · OPTI-AML Trial · View post ↗
“What would be your choice for unfavorable early-stage stage Hodgkin's if there was no reimbursement issues? Are we ready for Nivo-AVD?”
— @nico30f · Hodgkin's Lymphoma Treatment · View post ↗
“"Hispanic/Latino" was built for policy, not biology. In leukemia, treating it as one group hides real diversity in ancestry, access & disease.”
— @DrMonicaGuzman · Leukemia Research Demographics · View post ↗